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Abstract: The blood–brain barrier (BBB) plays a fundamental role in protecting and 
maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much 
more difficult than that to other compartments of the body. In order to bypass or cross the 
BBB, many strategies have been developed: invasive techniques, such as temporary disrup-
tion of the BBB or direct intraventricular and intracerebral administration of the drug, as 
well as noninvasive techniques. Preliminary results, reported in the large number of stud-
ies on the potential strategies for brain delivery, are encouraging, but it is far too early to 
draw any conclusion about the actual use of these therapeutic approaches. Among the most 
recent, but still pioneering, approaches related to the nasal mucosa properties, the permea-
bilization of the BBB via nasal mucosal engrafting can offer new potential opportunities. It 
should be emphasized that this surgical procedure is quite invasive, but the implication for 
patient outcome needs to be compared to the gold standard of direct intracranial injection, 
and evaluated whilst keeping in mind that central nervous system diseases and lysosomal 
storage diseases are chronic and severely debilitating and that up to now no therapy seems 
to be completely successful.
Keywords: CNS, BBB, nasal mucosa, grafting, lysosomal storage diseases, enzyme replace-
ment therapies
Introduction
There are more than 1,000 agents which are active on central nervous system (CNS) 
pathologies that have shown promising perspectives in preclinical studies but failed 
to show good results in the later phases of the development process (at Phase III or 
even after registration).1–5
For this reason, disorders of the CNS represent one of the largest areas of unsatis-
fied medical needs, with about 2 billion people affected worldwide and many pharma 
companies moving away from such fields of innovative research because of the high 
risk of failure associated with CNS medicines, together with the ever increasing 
approval time.6,7
One of the major reasons for the poor translation of neuroscience research into 
medicines is the high degree of complexity of the human CNS, and effective nonin-
vasive treatment of neurological diseases is often limited by the very limited access 
of therapeutic agents into the CNS owing to the presence of two anatomical and bio-
chemical dynamic barriers: the blood–brain barrier (BBB) and the blood–cerebrospinal 
fluid barrier (BCSFB).8
It is already well known that BBB is formed by endothelial cells (ECs), which line 
up in capillaries of the brain and spinal cord by a variety of pericytes, vascular smooth 
muscle cells, astrocytes, and microglia.9 The BBB, composed of densely packed cells 
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with copious intercellular tight junctions (TJs), active efflux 
pumps, and a trilamellar basement membrane, regulates the 
synaptic signaling function. Furthermore, BBB protects the 
CNS from neurotoxic substances, ensures brain nutrition, and 
prevents the entry of unwanted cells into the brain as well 
as the absorption of polar or high molecular weight (HMW) 
molecules larger than 500 Da; in other words, more than 98% 
of therapeutic drugs.10–12
The BBB also displays immunological and transporta-
tion features. The immune barrier is composed of microglia, 
perivascular mast cells, and macrophages. The transport 
barrier includes para- and transcellular routes. In addition, 
the brain is extremely rich in vascularity, with each neuron 
in contact with a capillary.13–15
The BCSFB is formed by the TJs of choroid plexus cells 
surrounding the microvascular endothelium with intracellular 
gap and fenestration. Owing to their structural difference, 
BBB and BCSFB have different main functions, but they 
both participate in controlling the transfer of molecules 
between the blood and the brain parenchyma or cerebrospinal 
fluid (CSF).
Under certain physiological conditions, circulating 
molecules can only gain access to the brain or CSF via 
a transcellular route through the capillary endothelial 
cells or choroid plexus cells, by either passive or active 
transport, or both.
Furthermore, if molecules overcome the BBB, they are 
not able to do so in high amounts, and they are exposed to 
degradation and/or rapid efflux from the CNS.16
Different transporters suitable for targeting molecules and 
delivering endogenous and exogenous compounds across the 
BBB are located on the BBB (Figure 1).
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Figure 1 Transport routes across the blood–brain barrier.
Note: Green lines indicate tight junctions; blue boxes indicate no carrier or receptor mediated transport.
Abbreviations: BBB, blood–brain barrier; RMT, receptor-mediated transcytosis; AMT, adsorptive-mediated transcytosis.
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All these highly regulated and efficient features supply 
BBB with multiple functions as a physical barrier (TJ), a 
transport barrier (P-gp), a metabolic or enzymatic barrier, 
and an immunological barrier.17,18
Functions and organization of the BBB can be altered 
under pathological conditions, such as multiple sclerosis, 
epilepsy, acquired immune deficiency syndrome (AIDS), 
dementia, stroke, and brain cancer.19,20
It should also be pointed out that alterations in the barrier, 
as in the blood–brain tumor barrier (BBTB), often form an 
increased obstacle in CNS therapy by preventing the delivery 
of potentially effective therapeutic agents.21
Molecular and physiological mechanisms involved in 
the transport of compounds through the BBB can be used to 
design drug and drug carriers for brain delivery.
Ligands such as peptides, monoclonal antibodies (mAbs), 
modified proteins, peptidomimetic antibodies, and penetrat-
ing peptides can be conjugated to bioactive compounds or to 
colloidal supramolecular aggregates and potentially used to 
cross the BBB and accumulate inside the CNS.22
The paradox is that more than 99% of the global CNS 
drug development effort is devoted to CNS drug discovery, 
while less than 1% is devoted to CNS drug delivery.23
Fortunately, scientists realized how important is the 
pathway from the systemic circulation to the CNS, and 
a few years ago, the Stroke Therapy Academic Industry 
Roundtable Preclinical Recommendations group highly 
recommended that future neurological disease research 
should consider also the method of drug delivery when 
developing novel drugs.24
Current methodologies for drug 
delivery across the BBB
In order to bypass or cross the BBB, many strategies have 
been developed: invasive techniques, such as temporary dis-
ruption of the BBB or intraventricular and intracerebral direct 
administration of the drug, and noninvasive techniques. The 
invasive strategies, however, compromise the integrity and 
the functions of the BBB, allowing the potential accumulation 
of neurotoxic xenobiotics and exogenous agents; a state that 
is moderately to severely neurotoxic.25,26
Noninvasive chemical approaches involve the “manipula-
tion” of active substances to be administered with the aim of 
increasing physiological stability and degree of penetration 
into the brain by passive diffusion or by active targeting. 
For this purpose, several methods have been proposed, such 
as the lipidization via addition of lipid-like molecules to 
the structure; the addition of molecules able to use specific 
endogenous transporters (eg, nutrients and other essential 
compounds), and the synthesis of prodrugs. Chemical modi-
fications can be considered a safe, noninvasive approach, but 
they need chemical or enzymatic in vivo transformations that 
sometimes may lead to the loss of therapeutic activity or the 
activation of the physiological defense mechanisms of the 
membrane pumping out exogenous compounds.
Along with chemical modifications, there is an increase 
in multidisciplinary investigations, intended to facilitate 
the crossing of BBB, that combine biological, nanotech-
nological, and even biophysical expertise. In this sense, 
the most recent approaches concern TJ opening (eg, 
through the utilization of compounds like bradykinin 
via second messengers), receptor-mediated, adsorptive-
mediated transportation (some potentially useful tech-
nologies based on receptor-mediated transcytosis are 
currently under clinical evaluation for brain tumor therapy – 
Clinicaltrials.gov: NCT01967810, NCT02048059, 
NCT01480583, NCT01386580, NCT01818713), and efflux 
pump inhibition by specific inhibitors that appears to be a 
strategy capable of delivering the drug to the brain without 
affecting the integrity of the endothelial layer and TJ that 
might cause toxicities. Also, energy-based physical methods, 
such as ultrasound, microwave, or electromagnetic fields, 
are under evaluation.
Another approach for the improvement of brain targeting 
is represented by the combination of the drug with the living 
cells, acting as Trojan horses that can cross the BBB.27–29
In recent times, much attention has been given to nano-
technology in many areas because of its significant potential 
for the successful treatment of severe diseases such as cancer 
and neurological diseases.
A promising noninvasive approach to brain delivery 
involves nanomedicine, which takes advantage of the pos-
sible assembly of several biomaterials that can provide 
a delivery platform, at nanoscale size, capable of raising 
brain levels of drug substances otherwise unable to cross 
the BBB.23,30
The success of a therapeutic strategy by means of nano-
carriers depends on their ability to entrap drugs, to penetrate 
through anatomical barriers, and to release the incorporated 
drugs, accompanied by a good stability in the nanometric 
size range.26
One possible strategy is the drug encapsulation into 
brain-targeted nanocarriers such as polymeric nanopar-
ticles, dendrimers, vesicular carriers, metal, and silicon. 
These nanocarriers can have an organic or inorganic core 
and a surface coating with organic moieties able to interact 
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with the biological system at a molecular level for crossing 
the BBB.31
Modification of nanocarrier surface by adsorption or 
covalent linking of hydrophilic polymers, such as PEG, 
polysorbate 80, or polysaccharides, leads to an increase in 
nanocarrier circulation in the blood, whereas the surface 
derivatization with molecules that recognize cellular 
receptors facilitates the penetration of nanoparticles through 
the BBB.32
The strategy often termed active targeting involves two 
types of transports: adsorptive-mediated transcytosis (AMT) 
and receptor-mediated transcytosis (RMT). The AMT has 
gained considerable attention because several studies assess 
that this strategy has the possibility to enhance the transport 
of nanocarriers across the BBB, using cationic proteins or 
cell-penetrating peptides.33 However, as AMT is a nonspecific 
process, conjugation of such cationic proteins will also increase 
the adsorptive uptake process of nanocarriers in other parts of 
the body, which may possibly create toxic and immunogenic 
concerns. Transport of nanocarriers to the brain using the 
RMT process is more specific than AMT. The RMT involves 
addition of endogenous molecules on the nanocarrier surface, 
which are substrates for specific receptors expressed on the 
BBB. Addition of proteins (eg, transferrin, lactoferrin, Apoli-
poprotein E [ApoE]); peptides (eg, glutathione); or antitrans-
ferrin receptor antibody OX26 on the surface of liposomes, 
polymeric nanoparticles, and lipidic nanoparticles significantly 
increased the BBB penetrations of such nanocarriers.34
Size of the nanocarrier along with surface charge, surface 
hydration, and targeting strategy are important characteristics 
for development of a successful brain-targeted nanocolloid 
drug delivery system for glioblastoma multiforme (GBM) 
treatment. Among various possible nanocarriers, liposomes, 
polymeric nanoparticles, and lipid nanocarriers are the most 
widely studied, and will be discussed in detail in the follow-
ing sections.
Preliminary results reported in the large number of 
studies on the potential strategies to overcome and/or cross 
the BBB are encouraging, but it is far too early to draw any 
conclusion about the actual practical applications of these 
therapeutic approaches.
Challenge in nasal delivery to CNS
Nasal delivery has conventionally been restricted to topically/
locally acting therapeutic agents for the treatment of nasal 
problems (eg, cold and nasal hypersensitivity). Recently, 
nasal route received increased attention as a substitute for 
oral and parenteral routes for several systemic therapeutic 
agents. The highly vascularized and immunogenic nasal 
mucosa allows fast onset of action, enhanced bioavailability 
and patient compliance.35–37
The pioneering method of intranasal delivery for drug 
delivery into the CNS was first described in 1991 by 
Dr William H Frey, and nowadays, it has proven to be a 
safe and efficient way to deliver exogenous molecules to 
the CNS.38–42 After nasal administration for CNS delivery, 
four physiological steps are possible, and they include the 
olfactory nerve pathway, trigeminal nerve pathway, vascular 
pathway, and the lymphatic pathway.43
During the last two decades, four areas, including intra-
nasal delivery validation, pathway elucidation, intranasal 
delivery of various therapeutics for the treatment of 
neurological diseases, and enhancement of the efficiency of 
intranasal delivery, have been explored.44,45
Nasal cavity delivery and nasal absorption are promising 
approaches but are still uncertain. Direct intranasal transport 
is not always well established, and controversial results were 
obtained when similar substances were administered, and 
sometimes, even opposite results have been reported after 
nasal delivery to the CSF.46,47
A few years ago, Merkus and van den Berg,48 reviewing 
more than 100 papers, reported that no significant phar-
macokinetic evidence was yet capable of establishing that, 
in humans, the intranasal route of administration actually 
provides enhanced targeting to the CNS, compared to the 
systemic route.
The real potential of the nasal route for drug delivery 
purposes clearly needs to be explored, developing new 
approaches and amending theories.37
Nasal mucosal properties (ie, permeability to very large 
and polar molecules), are used in recent but still pioneering 
approaches, and among the various techniques, the permea-
bilization of the BBB via nasal mucosal engrafting could 
offer new important opportunities.
Nasal mucosal grafting: potential for 
drug delivery and implications for 
enzyme replacement therapies
Nasal mucosal grafting
Over the last few decades, the management of anterior skull 
base defects, CSF leaks, and encephaloceles by endoscopic, 
minimally invasive approaches is improving. Whether the 
etiology of these defects is spontaneous, traumatic, or surgical 
(eg, removal of brain tumors through the nose without facial 
incisions), the large majority of such defects can be repaired 
by means of free mucosal grafts that can be applied as a 
single layer reconstruction for small leaks or as a multilayer 
reconstruction for larger defects.49
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Middle turbinate, inferior turbinate, and nasal septum can 
be used as donor sites for free mucosal grafts for endoscopic 
endonasal reconstruction of the skull base. In this sense, 
the harvest of a nasal floor free mucosal graft was recently 
proposed as a rapid, potentially less morbid method.50 
Accessibility, ease of placement, and high take rate make 
free mucosal grafts suitable candidates for reconstruction 
of many skull base defects.51
The repairs by mucosal grafts are permanent, watertight, 
and immunocompetent, and they can also be used to replace 
large regions of the BCSFB within the arachnoid with 
relatively permeable mucosa.52,53 In principle, the engrafted 
mucosa can be dosed with therapeutic agents applied 
topically. Given the lack of underlying arachnoid membrane, 
these mucosal grafts, using purely autologous tissues, could 
be proposed to solve problems related to the BBB crossing 
by HMW or polar agents and a direct delivery to the brain 
and to the subarachnoid space (Figure 2).
This approach was tested for the first time by Bleier 
et al54 in a proof-of-concept extracranial graft model in 
mice. The applied mucosal grafting method was adapted 
by a surgical technique that is currently used in the field 
of endoscopic skull base surgery defects.55 The ability of 
septal mucosal grafts to allow diffusion of HMW markers 
into the CNS was investigated. A murine model, mimick-
ing the human skull base, was developed and validated. 
A polypropylene reservoir, allowing topical dosing of the 
graft with different fluorescent markers (20–500 kDa), was 
surgically implanted over the mucosal graft. The whole 
mucosal implant was well tolerated, and no evidence of 
subcutaneous infection or distress related to the surgi-
cal site was observed. Furthermore, the delivery via the 
mucosal graft was compared to the intranasal delivery, and 
a minimal delivery, similar to that of the negative control 
(dura membrane kept intact), was obtained. The direct 
exposure of the brain to the marker solution was used as 
positive control (no intervening dura or nasal mucosa). 
This study showed that the mucosal grafts allowed good 
permeability to HMW molecules and that the transport rate 
seemed to be molecular weight dependent. By extending 
the exposure duration, this effect was partially overcome. 
By developing different drug eluting polymers, the release 
rate can be modulated over time, and this could be a great 
challenge in combining innovative surgical and technologi-
cal approaches.54
The interesting findings of this study are limited by the 
possibility of comparing an animal model to a clinical setting 
owing to regional differences in convection throughout the 
murine and human brain. First of all, in humans, the ratio 
between mucosal graft area and brain volume ratio is much 
higher. In addition, in the clinical application, diffusion to 
more distal regions of the brain can be possible via CSF 
circulation, while it should be quite impossible in the murine 
model because of the occlusion of the smaller subarachnoid 
space after craniotomy.
Despite the aforementioned limitations of nasal mucosal 
grafting, the delivery of glial-derived neurotrophic factor 
(GDNF) was investigated in a mouse model for the treat-
ment of Parkinson disease (PD).56 In this study, a murine 
6-hydroxydopamine PD model was applied. A parietal 
craniotomy and arachnoid defect was repaired with a 
heterotopic donor mucosal graft. Given the permeability 
of these mucosal grafts to HMW molecules, as previously 
reported, the possibility, by means of this approach, to 
????????????????
?????? ???????????????
?????
?????
????????????????????????
?????????????
Figure 2 Graphic description of nasal mucosa graft.
Notes: The area circled in red indicates the nasal mucosal grafting area; the green arrow indicates absorption direction; and the white boxed area indicates removed bone 
and dura/arachnoid.
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bypass the BBB and to deliver HMW neuroactive sub-
stances, engrafted over an arachnoid defect, directly to the 
CNS was evaluated.54
GDNF was released by a polypropylene reservoir placed 
over the mucosal graft. Cyanoacrylate adhesive was used 
to attach the reservoir to the skull, and dental cement was 
applied to the skull. To maintain structural integrity, two 
bone screws were implanted into the skull before cement 
application.
GDNF was delivered through the mucosal graft, and the 
therapeutic efficacy was evaluated and compared with direct 
intrastriatal GDNF injection using behavioral assays (rotarod 
and apomorphine rotation). To compare the preservation of 
substantia nigra cell bodies, an immunohistological analy-
sis was also used. Both behavioral and histological results 
demonstrated the therapeutic efficacy of transmucosal GDNF 
delivery. No significant difference was reported in neuronal 
survival between the transmucosal and injected GDNF mice, 
suggesting that the transmucosal pathway could be as effective 
as direct intraparenchymal injection in GDNF delivering to 
the end-target structures deep within the brain. Furthermore, 
the proposed mucosal grafting method could show advantages 
over the simple intranasal drug delivery while avoiding the 
concerns over the limitations of olfactory uptake in humans. 
In principle, the graft may be placed adjacent to the sphenoid 
sinus, which creates an intrinsic reservoir capable of retaining 
a greater volume of any intranasally applied solution. This 
reservoir can also help to enhance mucosal residence time by 
limiting the immediate clearance of the drug from the nose 
because of the mucociliary clearance.57
This chirurgical procedure can be an efficient method to 
assure drug localization in the CNS, especially in the case 
of HMW drugs, such as enzymes that are widely used in the 
treatment of lysosomal storage diseases.
The local effect of this surgical procedure is the replace-
ment of BBB and BCSFB, while the effect on the remain-
ing part of BBB and BCSFB has not been evaluated and is 
not easily predictable by the results reported in the three 
cited research papers. Furthermore, the long-term effects of 
grafting nasal mucosa have not yet been evaluated because 
this technique has only been reported in a few very recent 
experimental studies on mice.54–56
Lysosomal storage diseases
Lysosomal storage diseases (LSDs) include more than 
50 inherited metabolic disorders characterized by the 
intralysosomal accumulation of undegraded substrates. 
Chemical properties of the accumulated substrate allow 
classification of the different types of LSDs. Individually, 
these disorders are rare, but their cumulative prevalence is 
relatively high when compared with other groups of rare 
diseases, and they reach an incidence of one over 8,000 
newborns.58
LSDs are responsible for various clinical consequences 
on multiple organs and systems with visceral, ocular, hema-
tological, skeletal, and neurological manifestations, and there 
is partial phenotypic overlap among different disorders. 
Symptoms may emerge in utero, during the newborn period, 
or in late adulthood. About 75% of LSD patients present a 
neurological impairment.
LSDs are often responsible for physical and neurologi-
cal disabilities, and they can interfere with patients’ health 
and life expectancy. Therefore, the LSD therapy requires a 
multidisciplinary collaboration.
LSDs are caused by mutations in genes encoding soluble 
acidic hydrolases, integral membrane proteins, activator 
proteins, transporter proteins, or nonlysosomal proteins that 
are necessary for the lysosomal functions. These deficien-
cies are responsible for intralysosomal accumulation of 
undegraded substrates in multiple tissues and organs.
Perturbation of lysosomal function may also lead to less 
obvious consequences, such as PD, which is the prevalent 
neurodegenerative disorder. Histopathologically, PD is 
characterized by the accumulation of insoluble aggregates 
of the presynaptic protein α-synuclein in typical intran-
euronal inclusions (Lewy bodies), by the selective loss of 
dopaminergic neurons in the substantia nigra, and clinically 
by movement and postural defects. Although the mechanisms 
underlying this connection have not been fully elucidated, 
dysfunctions in several lysosomal proteins (and lysosomal 
gene mutations) have been involved in the pathogenesis 
of PD.
Mutations in gene encodings, essential components of 
the endolysosomal–autophagic pathway, have also been 
described in other neurodegenerative diseases, including 
Alzheimer disease, Huntington disease, frontotemporal 
dementia, and Charcot-Marie-Tooth type 2B.
In the past 25 years, much effort has been directed at 
developing specific therapies to correct the metabolic defects 
of these disorders by means of different strategies that were 
intended to target a specific event in the pathogenetic cascade, 
increasing the activity of the defective enzyme or protein by 
different ways.
The normal enzyme, obtained by recombinant technol-
ogy or its precursor secreted in the circulation by engineered 
cells, may be administered through the endocytic pathway, by 
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intravenous administration. It is also possible to correct the 
gene mutation by delivering a wild-type copy of the mutated 
gene or to protect from degradation the mutant enzyme by 
increasing its residual activity.
Other strategies, aimed at restoring the equilibrium 
between the synthesis of substrates and their degradation 
by lysosomal enzymes, have been studied. They include 
reduction of substrate synthesis, enhancement of the clear-
ance of substrates from cells and tissues, and manipula-
tion of specific cellular pathways, involved in vesicle 
trafficking (Figure 3).59
Moreover, alterations in the BBB are likely involved in 
LSDs as well as in all neurodegenerative diseases.60 Actu-
ally, neuroinflammatory changes present in neurodegenera-
tion commonly affect the BBB or its function by altering 
transport systems, affecting the integrity of TJ, enhancing 
immune cell entry, or influencing the BBB’s role as a sig-
naling interface.61 In addition, ion balance, disruption of 
transport systems, and altered function of BBB constitutive 
enzymes61,62 are also induced by BBB dysfunction. The 
BBB impairment influences drug therapy, in particular the 
process regulating the entry of drugs normally excluded 
from the brain.61,63
enzyme replacement therapy
Enzyme replacement therapy (ERT) is one of the approaches 
for several LSD treatments. In the early 1990s the efficacy 
of ERT in Gaucher disease was demon strated, and this 
approach has been used to treat other LSDs, including Fabry 
disease, Pompe disease, and Mucopolysaccharidosis I, II, 
and VI.64–71
After the conclusion of the first phase of ERT develop-
ment, advantages and limitations of this approach have 
emerged. Important limitations include the reduced bio-
availability of intravenously injected recombinant enzymes, 
and, therefore, strategies to improve ERT efficacy need to 
be identified. Recombinant enzymes are HMW molecules 
that are unlikely diffuse across membranes and are unable 
to reach therapeutic concentrations in some target tissues, 
particularly the brain. An additional major goal in future years 
should be the discovery of a BBB crossing enzyme because 
two-thirds of LSDs are involved in neurological symptoms 
and progressive neurodegeneration.
Strategies to improve the delivery of enzymes to the 
CNS are currently undergoing preclinical and clinical evalu-
ation. For example, β-glucuronidase, which is deficient in 
Mucopolysaccharidosis VII, has been chemically modified to 
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Figure 3 Schematic representation of therapeutic approaches to LSDs.
Abbreviations: LSDs, lysosomal storage diseases; eRT, enzyme replacement therapy.
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increase its plasma half-life and facilitate its traffic through 
the BBB.72,73 Other approaches consider the use of so-called 
Trojan horses, made of chimeric enzymes conjugated with 
peptides that can allow penetration through the BBB leading 
to brain delivery by specific pathways such as the apolipo-
protein and receptor pathways. These approaches have been 
evaluated in preclinical studies for α-iduronidase, iduronate-
2-sulfatase, arylsulfatase A, and tripeptidyl peptidase I.74–78
In addition to these approaches, preclinical studies 
are evaluating the use of invasive procedures to deliver 
recombinant enzymes directly into the CSF for the treat-
ment of several lysosomal disorders. Intrathecal and lum-
bar or cisterna magna punctures have been studied for the 
administration of various types of mucopolysaccharidoses 
in animal models.79–82 Intrathecal ERT has been translated 
into human therapy for mucopolysaccharidoses types I and 
VI. Devices for continuous intrathecal infusion have been 
developed and tested in preclinical studies. Some clinical 
trials of intrathecal administration of ERT are ongoing, and 
others have been completed. Invasive techniques for BBB 
crossing were based on neurosurgery or on a temporary 
chemical/physical disruption of the barrier, produced by 
biochemical and immunological changes or by an osmotic 
shift.83–85 However, both these approaches entail several 
drawbacks such as the invasiveness and the high costs of neu-
rosurgery, the physiological stress, or the transient increase 
in the intracranial pressure, along with high risk of infec-
tions and damages from toxins, due to the BBB temporary 
opening. Therefore, to improve drug delivery to the brain, 
noninvasive techniques have been explored, and among them 
the nanotechnology-based approach surely represents one of 
the most encouraging procedures.
To obtain a selective targeting to receptors highly 
expressed on the BBB, several possible ligands have been 
identified including transferrin, lactoferrin, insulin and leptin, 
and the LDL-receptor related protein LRP1.11 The proposed 
nanocarriers include a wide variety of drug-delivery vehi-
cles, including dendrimers, micelles, liposomes, nanoscale 
ceramics, and polymer nanoparticles.86–88 Different carriers 
offer different approaches to enzyme delivery. Liposomes 
are the first generation of nanoparticulate drug-delivery 
systems that reached the market, and they consist of one or 
more phospholipid bilayers delimiting an internal aqueous 
compartment. They are able to deliver hydrophobic, hydro-
philic, and amphiphilic molecules. It has been reported that 
β-galactosidase loaded liposomes injected by rat tail vein 
can penetrate the BBB and reach the lysosomes in the CNS 
more efficiently than the free enzyme.89 Similar results 
have been obtained by ex vivo and in vivo studies on 
saposin C-loaded liposomes that improve the neurologi-
cal condition.90 Liposomes modified with lysosomotropic 
octadecyl-rhodamine B (Rh) and loaded with therapeutic 
glucocerebroside velaglucerase α (VPRIVTM) increase 
lysosomal delivery of the enzyme into Gaucher cells.91 
Biodegradable and biocompatible nanoparticles, composed 
of poly (d,l-lactide-co-glycolide) (PLGA), have been inves-
tigated for recombinant proteins, plasmid DNA, and low 
molecular weight compounds brain delivery.92 Recently, 
in vitro and in vivo animal studies demonstrated the ability of 
PLGA nanoparticles, modified with glycopeptides (g7-NPs), 
to efficiently cross the BBB and to be transported intra- and 
intercellularly within vesicles for a more effective treatment 
of neurological disorders.93–95 Pegylated immunoliposomes, 
derivatized with the 8D3 antitransferrin receptor antibody, 
have been used to target the luciferase and α-galactosidase 
genes into the rat brain and to assure their activity after 
intracellular delivery.
Systemic gene therapy, together with several recombi-
nant vector systems, is under evaluation and appears to be 
promising.96,97 Finally, it was shown that hemopoietic stem 
cells, derived from the monocyte/macrophage lineage and 
genetically modified to produce replacement enzymes, are 
capable of crossing the BBB in rodent models and enter-
ing into the CNS.98,99 However, so far neither nanocarriers 
nor adeno-associated virus vectors nor cell-based therapies 
capable of crossing the BBB have reached clinical trials in 
LSD, for both technological and toxicological problems.
Conclusion
The BBB plays a fundamental role in protecting and main-
taining the homeostasis of the brain. For this reason, drug 
delivery to the brain is much more difficult than to other 
compartments of the body. The brain capillary endothelium 
excludes from the brain around 100% of large-molecule and 
more than 98% of small-molecule drugs.
Consequently, possible therapies with charged or mac-
romolecular drugs, which could be capable of preventing or 
even reversing certain neurologic diseases, are actually clini-
cally ineffective owing to their inability to cross the BBB. 
This is the central and crucial problem for an effective treat-
ment of both LSDs and the associated neuropathology.
The fact that therapeutic approaches capable of modify-
ing the natural evolution of many LSDs in the peripheral 
organs have been published and/or are under development 
(eg, enzyme replacement therapy, nanotechnology, gene 
therapy, and the use of stem cells) makes LSDs the ideal 
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environment in which to further investigate the relationship 
between lysosomal dysfunction-related neurodegeneration 
and the development of new strategies capable of crossing 
the BBB and reaching the brain compartment.
A number of studies showed that, in neurodegenerative 
diseases and LSDs, the function and integrity of the BBB and, 
in particular, of TJ, might be compromised. In these condi-
tions, an increased passive extravasation of solutes, including 
proteins up to at least a molecular weight of 150 kDa, into 
the brain can be demonstrated. In general, damage to the 
BBB can induce even worse CNS damages. Furthermore, 
the neuropathology, related to the accumulation of storage 
products, and the correlation between the two processes, 
needs to be better understood.
It must be clarified that the ERT treatment or other 
approaches must bypass the BBB barrier function. At present, 
the best way to reach the CNS crossing the BBB, whether by 
a clinical approach or a technological one using innovative 
drug delivery systems, is not clearly defined. Valid results 
obtained on a large-animal are still not available and the 
nasal mucosal grafting approach appears not yet feasible for 
clinical translation.
Mucosal grafting requires an endoscopic procedure, 
and this can seriously limit patient compliance. However, 
because the grafting technique is adapted from an existing 
endoscopic surgical procedure, its safety profile has been 
well established over several decades of clinical use and is 
associated with a lower morbidity rate than other currently 
accepted methods of BBB invasive penetration. It should be 
emphasized that this surgical procedure is quite invasive, but 
at present, patients are subjected to direct intracranial injec-
tion that is not always tolerated, because neurodegenerative 
diseases and LSDs are chronic and severely debilitating 
diseases, and to this day no therapy seems to be completely 
successful.100–102
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